The Business of Pain Medicine: The Present Mirrors Antiquity

Pain Medicine

Volumn 12, Issue 7, 2011, Pages 1063-1075

  Kulich, Ronald ^a,b   Loeser, John D ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ethics; Historical; Liability; Pain medicine; Public policy

Indexed keywords

ARTICLE; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; MEDICAL ETHICS; MEDICAL LIABILITY; PAIN; PATIENT CARE;

EID: 79960370820     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01176.x     Document Type: Article

References (64)

1. Kirch DG. The healthcare innovation zone: A platform for true reform. JAMA 2010;303(9):874-5.
2. Fuchs VR. Health reform: Getting the essentials right. Health Aff 2009;28(2):w180-3.
3. Dubois MY, Banja J, Rushwood D, etal. Ethics charter from American Academy of Pain Medicine. Pain Med 2005;6(3):203-12.
4. Fox CD, Berger D, Fine PG, etal. Pain assessment and treatment in the managed care environment. A position statement from the American Pain Society. Approved January 11, 2000. 2000.Available at: (accessed Oct 2010).
5. Lande S, Kulich RJ, eds. Managed Care and Pain. Glenview, IL: American Pain Society; 2000.
6. Kulich R, Adolph M. Multidisciplinary chronic pain treatment: Minimizing financial risk. In: Shatman M, Campbell A, eds. Chronic Pain Management: Guidelines for Multidisciplinary Program Development. New York: Informa Healthcare; 2007:241-62.
7. Loeser JD. The future: Will pain be abolished or just pain specialists? International association for the study of pain. Clin Updates 2000;8(6):1-4.
8. Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain 2006;7(11):779-93.
9. Clark ME. Cost-effectiveness of multidisciplinary pain treatment: Are we there yet? Pain Med 2009;10(5):778-9.
10. Steinbrook R. Controlling conflict of interest-proposals from the institute of medicine. N Engl J Med 2009;360(21):2160-3.
11. Chou R, Fanciullo GJ, Fine PG, etal. Opioid treatment guidelines: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30.
12. Gardiner HG, Carey B. Researchers fail to reveal full drug pay. New York Times June 8, 2008.
13. Walsh C. Medical school revises conflict of interest policy. Strengthens commitment to transparency, financial disclosure. Harvard Science 2010. Available at (accessed June 2011).
14. Ehringhaus SH, Weissman JS, Sears JL, etal. Responses of medical schools to institutional conflicts of interest. JAMA 2008;299(6):665-71.
15. Mitchell PD. Medicine in the Crusades. Warfare, Wounds and the Medieval Surgeon. Cambridge, UK: Cambridge University Press; 2005.
16. Mohr JC. American medical malpractice litigation in historical perspective. JAMA 2000;283(13):1731-7.
17. Dormandy T. The Worse of Evils, The Fight against Pain. New Haven, CT: Yale University Press; 2006.
18. French R, Greenaway F. Science in the Early Roman Empire: Pliny the Elder, His Sources and Influence. London: Croom Helm; 1986.
19. Holmes OW. Medical Essays, 1842-1882 The Project Gutenberg EBook of Medical Essays, by Oliver Wendell Holmes, Sr. Beverly Farms, MA: Project Gutenberg; 1891.Available at: (accessed August 2010).
20. Holmes OW. Homoeopathy, and Its Kindred Delusions; Two Lectures Delivered before the Boston Society for the Diffusion of Useful Knowledge. Boston: William D. Ticknor; 1842.
21. Holmes OW. The Medical Profession in Massachusetts, A Lecture of a Course by Members of the Massachusetts Historical Society, Delivered before the Lowell Institute, January 29, 1869. Proceedings of the Massachusetts Historical Society, 1871-1873. Cambridge, MA: John Wilson and Son; 1973.
22. Tsai GF. Ancient Chinese medical ethics and the four principles of biomedical ethics. J Med Ethics 1999;25:315-21.
23. Steig RL. Financing the treatment of chronic pain, Models of risk sharing among pain medicine physicians, healthcare payers and consumers. Pain Med 2000;1(1):78-88.
24. Angarola RT, Jorhanson DE. State pain commissions, new vehicles for progress. Am Pain Soc Bull 1996;6:7-9.
25. Lande S. The Dynamics of Pain Management Within Today's Managed Care Environment. Report of the American Pain Society Managed Care Roundtable Held in San Francisco, September 15, 199. Glenview, IL: American Pain Society; 1997.
26. Rose FC. Trigeminal neuralgia. Arch Neurol 1999;56:1163-4.
27. Dewhurst K. A symposium on trigeminal neuralgia, with contributions by Locke, Sydenham, and other eminent seventeenth-century physicians. J Hist Med Allied Sci 1957;12:21-36.
28. Stookey B, Ransohoff J. Trigeminal Neuralgia: Its History and Treatment. Springfield, IL: Charles Thomas; 1959.
29. Earle P. The Making of the English Middle Class: Business, Society and Family Life in London 1660-1730. Berkeley, CA: University of California Press; 1989.
30. Carr DB. When bad evidence happens to good treatments. Reg Anesth Pain Med 2008;33(3):229-40.
31. McNutt RA, Livingston EH. Evidence-based medicine requires appropriate clinical context. JAMA 2010;303(5):454-5.
32. Finger S. Doctor Franklin's Medicine. Philadelphia, PA: University of Pennsylvania Press; 2006.
33. Franklin B. Report of the commissioners charged by the King in the examination of animal magnetism (originally published 1784), English translation in Skeptic. Magazine of the Skeptic Society, 4, 3, 1996.
34. Gravitz MA. The first use of self-hypnosis: Mesmer mesmerizes Mesmer. Am J Clin Hypn 1994;37(1):49-52.
35. Pattie FA. Mesmer and Animal Magnetism: A Chapter in the History of Medicine. Edmonton, Canada: Edmonston Publishing Inc; 1994.
36. Haygarth EJ. On the imagination as a cause & as a cure of disorders of the body. 1799. Referenced by Holmes (1842). Homoeopathy, and its Kindred Delusions; two lectures delivered before the Boston society for the diffusion of useful knowledge. Boston: William D. Ticknor, 1842. Available at: (accessed May 2010).
37. Conrad P, Leiter V. From Lydia Pinkham to Queen Levitra: Direct-to-consumer advertising and medicalisation. Sociol Health Illn 2008;30(6):825-38.
38. Buchanan WW, Kean WF. The treatment acute rheumatism by salicin, by T.J. Maclagan-Lancet, 1876. J Rheumatol 2002;29(6):1321-3.
39. Jeffreys D. Aspirin. The Remarkable Story of A Wonder Drug. New York: Bloomsbury Publishing; 2004:155.
40. Ohio State Medical Society. 15th annual meeting, June 12-14, 1860. 75-100. Trancripts Original Report (accessed August 2010).
41. McTavish JR. Pain and Profits, the History of the Headache and Its Remedies in America. New Brunswick, NJ: Rutgers University Press; 2004.
42. Wolfe RJ. Tarnished Idol: William Thomas Green Morton and the Introduction of Surgical Anesthesia: A Chronicle of the Ether Controversy. Biography Series, No. 1, Norman Landmarks Series, No. 3; Norman Science/Technology Series, No. 6; Norman Surgery Series, No. 11. San Anselmo, CA: Norman Publishing, 2001.
43. Dallas Morning News, Sept 3, 1851.
44. Tilton EM. Amiable Autocrat: A Biography of Dr. Oliver Wendell Holmes. New York, NY: Henry Schuman Pub.; 1947.
45. Dowling WC. Oliver Wendell Holmes in Paris: Medicine, Theology, and the Autocrat of the Breakfast Table. Hanover, NH: University Press of New England; 2006.
46. Kandall SR. Substance and Shadow; A History of Women and Addiction in the United States, 1850 to the Present. Cambridge, MA: Harvard University Press; 1996.
47. Angell M. Over and above: Excess in the pharmaceutical industry. CMAJ 2004;171:1451.
48. Wolfe MM, Lichtenstein DR, Singh G. Medical progress: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
49. Kuehn BM. Safety plan for opioids meets resistance opioid-linked deaths continue to soar. JAMA 2010;303(6):495-7.
50. Strassels SA. After all, pain is a complex sensory and emotional experience, (IASP, 1994), clinical economics and the treatment of persistent pain. J Pain 2006;7(11):802-3.
51. Applbaum K. Pharmaceutical marketing and the invention of the medical consumer. PLoS Med 2006;3:e189.
52. Applbaum K. Is marketing the enemy of pharmaceutical industry? Hastings center report. Project Muse 2009;39(4):13-7.
53. Humphreys G. Direct-to-consumer advertising under fire. Bull World Health Organ 2009;89(9):576-7.
54. Mintzes B. Disease mongering in drug promotion: Do governments have a regulatory role? PLoS Med 2006;3:e198.
55. Moynihan R, Henry D. The fight against disease mongering: Generating knowledge for action. PLoS Med 2006;3:e191, e314-7.
56. Bynum WF, Forter R, Shepherd M. The Anatomy of Madness, Essays in the History of Psychiatry, Volume 1, People and Ideas. London: Tavistock Publications; 1985.
57. Scheper-Hughes N, Lock MM. Speaking "truth" to illness: Metaphors, reification, and a pedagogy for patients. Med Anthropol Q 1986;1(4):137-40.
58. Martin Kaufman M. Homeopathy in America, the Rise and Fall of a Medical Heresy. Baltimore, MD: Johns Hopkins University Press; 1972.
59. Humphreys F. Humphreys Homeopathic Mentor or Family Advisor. New York: Humphrey's Specific Homeopathic Medicine Company; 1879.
60. Insel TR. Psychiatrists' relationships with pharmaceutical companies: Part of the problem or part of the solution? JAMA 2010;303(12):1192-3.
61. DeAngelis CD, Fontanarosa PB. Ensuring integrity in industry-sponsored research: Primum non nocere, revisited. JAMA 2010;303(12):1196-8.
62. McPartland JM. Reject influence of pharmaceutical industry. J Am Osteopath Assoc 2009;109:655.
63. Graf C, Battisti WP, Bridges D, etal. Research methods & reporting good publication practice for communicating company sponsored medical research: The GPP2 guidelines. BMJ 2009;339:b4330.
64. Angell M. Industry-sponsored clinical research: A broken system. JAMA 2008;300(9):1069-71.